2018
DOI: 10.3389/fmed.2018.00240
|View full text |Cite
|
Sign up to set email alerts
|

Fertility Sparing Treatment in Patients With Early Stage Endometrial Cancer, Using a Combination of Surgery and GnRH Agonist: A Monocentric Retrospective Study and Review of the Literature

Abstract: Objectives: To evaluate the efficacy and safety of gonadotropin-releasing hormone (GnRH) agonist after endometrial resection in women suffering early stage endometrial carcinoma (EC) and/or endometrial intra-epithelial neoplasia (EIN).Design: A retrospective review of clinical files between January 1999 and December 2016.Setting: University hospital.Patients: Eighteen women younger than 41 years with grade 1 endometrial carcinoma (G1EC) and/or Endometrial intra-epithelial neoplasia (EIN). Interventions: All pa… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
46
1

Year Published

2019
2019
2023
2023

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 47 publications
(53 citation statements)
references
References 43 publications
1
46
1
Order By: Relevance
“…Endometrial cancer treatment often involves surgical removal of the uterus, ovaries, uterine tubes, and pelvic and paraaortic lymph nodes [40]. In the case of reproductive-aged women, fertility-sparing treatment is possible, however, it requires further standardization and development in order to provide the patient with access to various solutions [41,42]. It is important to look for complementary molecular markers that allow for an earlier and more precise diagnosis, as it can provide more treatment options and allow for the development of strategies that will be as non-invasive as possible for the patient.…”
Section: Discussionmentioning
confidence: 99%
“…Endometrial cancer treatment often involves surgical removal of the uterus, ovaries, uterine tubes, and pelvic and paraaortic lymph nodes [40]. In the case of reproductive-aged women, fertility-sparing treatment is possible, however, it requires further standardization and development in order to provide the patient with access to various solutions [41,42]. It is important to look for complementary molecular markers that allow for an earlier and more precise diagnosis, as it can provide more treatment options and allow for the development of strategies that will be as non-invasive as possible for the patient.…”
Section: Discussionmentioning
confidence: 99%
“…Once lymphatic metastasis (LM) occurs, the prognosis is very poor. 2 According to the International Federation of Gynecology and Obstetrics (FIGO) 2009 staging system, the proportions of stage IIIC1 and IIIC2 tumors in patients with EC are 2.3% and 1.2%, respectively. The 5-year survival rates for patients with stage IIIC1 and IIIC2 tumors are 57.0% and 49.4%, respectively.…”
Section: Introductionmentioning
confidence: 99%
“…Endometrial sampling was performed by hysteroscopy at the initial diagnosis and every 3 months during treatment. The histologies were reviewed according to the World Health Organization system by two pathologists specializing in gynecologic oncology 9. After a pathological complete response, the patients were monitored for recurrence every 3–6 months.…”
Section: Introductionmentioning
confidence: 99%